Chikungunya virus: an update on antiviral development and challenges

Drug Discov Today. 2013 Oct;18(19-20):969-83. doi: 10.1016/j.drudis.2013.05.002. Epub 2013 May 15.


Chikungunya virus (CHIKV) has re-emerged as a significant public health threat since the 2005 chikungunya fever epidemic in La Réunion. Driven by the medical importance of this virus, as well as the lack of approved antivirals, research into the field of CHIKV antivirals has recently intensified. Potential therapeutics that have been reported to show anti-CHIKV activity in vitro range from known broad-spectrum antivirals like chloroquine to novel strategies involving RNA silencing technology. Although most of the earlier efforts focused on compounds that target host components, some recent studies have reported viral targets such as nonstructural proteins. This article examines the reported in vitro and in vivo efficacies, as well as the therapeutic potential of these antiviral compounds.

Publication types

  • Review

MeSH terms

  • Alphavirus Infections / drug therapy*
  • Alphavirus Infections / metabolism
  • Animals
  • Antiviral Agents / chemistry*
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Chikungunya Fever
  • Chikungunya virus / drug effects*
  • Chikungunya virus / physiology
  • Drug Discovery / methods
  • Drug Discovery / trends*
  • Humans


  • Antiviral Agents